114 related articles for article (PubMed ID: 415443)
21. [Plasma and tissues distribution of misonidazole (RO 07-0582) in the rat bearing a chimio induced tumor (author's transl)].
Akel G; Canal P; Bugat R; Soula G; Combes PF
J Pharmacol; 1981; 12(4):383-91. PubMed ID: 7321570
[TBL] [Abstract][Full Text] [Related]
22. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
Palcic B; Faddegon B; Skarsgard LD
Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
[TBL] [Abstract][Full Text] [Related]
23. The hypoxic cell sensitizer programme in the United States.
Phillips TL; Wasserman TH; JohnsonRJ ; Gomer CJ; Lawrence GA; Levine ML; Sadee W; Penta JS; Rubin DJ
Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
[TBL] [Abstract][Full Text] [Related]
24. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic properties of antileukemic and trypanocidal compounds with amidino and imidazolinyl groups.
Gluth WP; Busch U
Arzneimittelforschung; 1984; 34(11):1542-51. PubMed ID: 6543129
[TBL] [Abstract][Full Text] [Related]
26. Toxicology and Carcinogenesis Studies of Furosemide (CAS No. 54-31-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 May; 356():1-190. PubMed ID: 12695785
[TBL] [Abstract][Full Text] [Related]
27. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
28. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
Saunders MI; Dische S; Fermont D; Bishop A; Lenox-Smith I; Allen JG; Malcolm SL
Br J Cancer; 1982 Nov; 46(5):706-10. PubMed ID: 7171452
[TBL] [Abstract][Full Text] [Related]
29. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
Stratford MR; Minchinton AI; Dische S; Saunders MI; Anderson P
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):377-9. PubMed ID: 7107355
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Roberts JT; Bleehen NM; Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic studies using multiple administration of RO 03-8799, a 2-nitroimidazole radiosensitizer.
Stratford MR; Minchinton AI; Hill SA; McNally NJ; Williams MV
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):469-71. PubMed ID: 7107368
[TBL] [Abstract][Full Text] [Related]
32. Cellular uptake of misonidazole and analogues with acidic or basic functions.
Dennis MF; Stratford MR; Wardman P; Watts ME
Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jun; 47(6):629-43. PubMed ID: 3873433
[TBL] [Abstract][Full Text] [Related]
33. The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
Dische S; Saunders MI; Riley PJ; Hauck J; Bennett MH; Stratford MR; Minchinton AI
Br J Cancer; 1981 Mar; 43(3):344-9. PubMed ID: 7225285
[TBL] [Abstract][Full Text] [Related]
34. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
Timothy AR; Overgaard J; Overgaard M
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1765-8. PubMed ID: 6480460
[TBL] [Abstract][Full Text] [Related]
35. A drug for improved radiosensitization in radiotherapy.
Dische S; Fowler JF; Saunders MI; Stratford MR; Anderson P; Minchinton AI; Lee ME
Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
[No Abstract] [Full Text] [Related]
36. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers.
Agrawal KC; Larroquette CA; Garg PK
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1301-5. PubMed ID: 6469754
[TBL] [Abstract][Full Text] [Related]
38. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
Workman P
Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
White RA; Workman P
Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
[TBL] [Abstract][Full Text] [Related]
40. Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.
Akel G; Benard P; Canal P; Soula G
Cancer Chemother Pharmacol; 1986; 17(2):121-6. PubMed ID: 3719893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
